Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
38.06
-0.43 (-1.12%)
Jul 31, 2026, 4:00 PM EDT - Market closed
Celldex Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.87 | 1.55 | 7.02 | 6.88 | 2.36 | 4.65 | |
Revenue Growth | -88.54% | -77.99% | 1.99% | 192.02% | -49.32% | -37.30% |
Gross Profit | 0.87 | 1.55 | 7.02 | 6.88 | 2.36 | 4.65 |
Selling, General & Admin | 44.47 | 43.84 | 38.55 | 30.91 | 27.2 | 20.49 |
Research & Development | 265.46 | 245.07 | 163.55 | 118.01 | 82.26 | 53.31 |
Other Operating Expenses | - | - | - | 12.5 | 8.14 | 2.1 |
Total Operating Expenses | 309.93 | 288.91 | 202.1 | 161.43 | 117.59 | 75.89 |
Operating Income | -309.06 | -287.37 | -195.08 | -154.54 | -115.23 | -71.24 |
Interest Income | 25.42 | 28.61 | 37.22 | 13.11 | 2.91 | 0.51 |
Total Non-Operating Income (Expense) | 25.42 | 28.61 | 37.22 | 13.11 | 2.91 | 0.51 |
Pretax Income | -283.65 | -258.76 | -157.86 | -141.43 | -112.33 | -70.74 |
Provision for Income Taxes | - | - | - | - | - | -0.23 |
Net Income | -283.65 | -258.76 | -157.86 | -141.43 | -112.33 | -70.51 |
Net Income to Common | -283.65 | -258.76 | -157.86 | -141.43 | -112.33 | -70.51 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 66 | 66 | 64 | 48 | 47 | 43 |
Shares Outstanding (Diluted) | 66 | 66 | 64 | 48 | 47 | 43 |
Shares Change | 0.31% | 3.15% | 32.91% | 3.33% | 9.37% | 44.64% |
EPS (Basic) | -4.26 | -3.90 | -2.45 | -2.92 | -2.40 | -1.64 |
EPS (Diluted) | -4.26 | -3.90 | -2.45 | -2.92 | -2.40 | -1.64 |
EPS Growth | - | - | - | - | - | - |
Free Cash Flow | -226.25 | -213.66 | -159.7 | -109.11 | -105.56 | -62.16 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -3.40 | -3.22 | -2.48 | -2.25 | -2.25 | -1.45 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -35688.50% | -18599.80% | -2778.89% | -2245.27% | -4889.01% | -1531.78% |
Profit Margin | -32753.60% | -16748.00% | -2248.76% | -2054.76% | -4765.59% | -1516.04% |
FCF Margin | -26125.80% | -13829.10% | -2274.89% | -1585.20% | -4478.57% | -1336.44% |
EBITDA | -305.7 | -283.99 | -191.9 | -151.53 | -112.34 | -68.18 |
EBITDA Margin | -35299.70% | -18381.00% | -2733.63% | -2201.57% | -4766.14% | -1465.81% |
EBIT | -309.06 | -287.37 | -195.08 | -154.54 | -115.23 | -71.24 |
EBIT Margin | -35688.50% | -18599.80% | -2778.89% | -2245.27% | -4889.01% | -1531.78% |
Effective Tax Rate | - | 0.00% | 0.00% | 0.00% | 0.00% | 0.32% |